These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19683860)

  • 1. The role of biopsy core number in selecting prostate cancer patients for active surveillance.
    Ploussard G; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    Eur Urol; 2009 Dec; 56(6):891-8. PubMed ID: 19683860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
    Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selection of patients for active surveillance: could it be perfect?
    Suardi N
    Eur Urol; 2009 Dec; 56(6):899-900; discussion 901-2. PubMed ID: 19762143
    [No Abstract]   [Full Text] [Related]  

  • 4. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy.
    Lee MC; Dong F; Stephenson AJ; Jones JS; Magi-Galluzzi C; Klein EA
    Eur Urol; 2010 Jul; 58(1):90-5. PubMed ID: 19875227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
    BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
    Lowe BA; Lieberman SF
    J Urol; 1997 Oct; 158(4):1452-6. PubMed ID: 9302141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE.
    Greene KL; Elkin EP; Karapetian A; Duchane J; Carroll PR; Kane CJ;
    J Urol; 2006 Jan; 175(1):125-9; discussion 129. PubMed ID: 16406887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
    Abouassaly R; Lane BR; Jones JS
    Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
    Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
    Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
    J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.
    Partin AW; Piantadosi S; Sanda MG; Epstein JI; Marshall FF; Mohler JL; Brendler CB; Walsh PC; Simons JW
    Urology; 1995 May; 45(5):831-8. PubMed ID: 7538245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
    Reese AC; Cooperberg MR; Carroll PR
    J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.